Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor

María-Consuelo Pintado1,2*, Lara Maceda3, María Trascasa1, Ignacio Arribas4 and Raúl De Pablo2,5

Abstract

Background: Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte growth factor have been associated with poor outcome in patients with acute myocardial infarction. The aim of this study is to evaluate the early prognostic value of measurements of copeptin and hepatocyte growth factor for hospital mortality risk and 1-year-follow-up mortality, in patients with acute myocardial infarction. In our retrospective observational study, we measured hepatocyte growth factor and copeptin in blood samples collected at hospital arrival in patients with acute myocardial infarction; and follow-up them until 1-year.

Results: 84 patients with were included in the study, mainly male (65%) with a median age of 70.3 ± 13.56 years. Hospital mortality was 11.9%. Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.60 pmol/L [52.21–588.50] vs. 24.79 pmol/L [10.90–84.82], p < 0.01). However, we found no statistically significant association between plasma levels of hepatocyte growth factor and hospital mortality (381.05 pg/ml [189.95–736.65] vs. 355.24 pg/ml [175.55–521.76], p = 0.73). 1-year follow-up mortality was 21.4%. Plasma levels of copeptin at hospital arrival were higher in those patients who died in the following year (112.28 pmol/L [25.10–418.27] vs. 23.82 pmol/L [10.96–77.30], p = 0.02). In the case of HGF, we also find no association between hepatocyte growth factor plasma levels and 1-year follow-up mortality (350.00 pg/ml [175.05–555.08] vs. 345.53 pg/ml [183.68–561.15], p = 0.68).

Conclusions: In patients with acute myocardial infarction measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of hepatocyte growth factor measurement.

Keywords: Hepatocyte growth factor, Copeptin, Myocardial infarction, Prognosis, Hospital mortality, Follow-up study
Copeptin is the C-terminal part of pro-arginine vasopressin. It is secreted in equimolar amounts than anti-diuretic hormone in response to changes in plasma osmolarity and reduced cardiac output; although it exact function is unknown. Several studies had shown that it levels increases early on an acute MI (< 3 h), even when other biomarkers are still negative [3]. It is postulated that endogenous stress that occurs during MI activates the arginine vasopressin system independently of cardiac cell necrosis and leads to an increase of vasopressin copeptin secretion [4, 5]. A meta-analysis [6] of diagnostic accuracy of copeptin combined with cardiac troponin, to rule out acute MI in Emergency Department, showed a high sensitivity (96%) but low specificity (56%). So currently, it is not recommended for diagnoses of early acute MI [1].

In patients with acute MI, copeptin have been associated with poor outcome: higher mortality [7, 8], development of ventricular dysfunction [9] or heart failure [10].

Hepatocyte growth factor (HGF) is produced by stromal cells, being the liver the major organ through which HGF is eliminated from circulation. Originally identified as a mitogen of hepatocytes and, later, reported to have diverse activities in various cell types: regenerative, anti-apoptotic and anti-fibrotic effects [11]. In clinical studies, plasma HGF concentrations showed an early increase in patients with cardiac infarction (within 3 h after cardiac infarction), followed by a rapid decline in their levels during the first 24 h of MI, to remain stable for up to one year [12–14]. In other studies, HGF has been reported as a marker of arteriosclerosis [15], peripheral arterial occlusive disease [16] and incident coronary heart disease [17]; also, it has been associated with poor prognosis in acute coronary syndromes [12, 18].

The main objective of this study is to evaluate the early prognostic value of measurements of copeptin and HGF at hospital arrival for hospital mortality risk, in patients with acute myocardial infarction. The secondary objective is to explore the association of them with 1-year-follow-up mortality.

**Methods**

**Study design and setting**

This retrospective, observational study was carried out in a University Hospital of Madrid, Spain, over a period of eight months. The study was approved by the Institutional Ethics and Clinical Trials Committee of University Hospital Príncipe de Asturias. Written informed consent was obtained from the patients. Neither, the researchers nor the subjects recruited in this study, received any fees or material incentives for their participation. This study did not receive financial or logistical support from any institution outside the Service or the Hospital where the study was carried out.

**Selection of participants**

We included all consecutive patients diagnosed of type 1 acute MI at hospital arrival during an 8-months period. Patients younger than 18-years-old, at terminal stage of any illness, life expectancy of less than one year, or who refusal to sign the consent to participate in the study, were excluded from our study.

The final diagnosis was made by a Cardiologist, according to the clinical data, electrocardiogram, echocardiogram and the determination of cardiac troponin, following to the international clinical guidelines of acute coronary syndrome [1, 2, 19].

**Measurements and interventions**

The data compiled from the patients included in our study were: demographic characteristics; risk factors for ACS; previous history of ACS; concomitant diseases; current treatment; Global Registry of Acute Coronary Events (GRACE) risk score [20] and Thrombolysis in Myocardial Infarction (TIMI) risk score [21]; in-hospital and after one-year follow-up mortality.

We retrospectively measured HGF and copeptin in blood samples collected from patients at hospital arrival, when the diagnosis of acute MI was confirmed by Cardiologist during the first 48 h after hospital admission. Prospectively, we follow-up the patients until hospital discharge and 1-year follow-up after twelve months of study inclusion. 1-year follow-up was carried out by telephone interview. If contact with participants was not possible, data were collected from the closest relatives, legal surrogate or medical records.

During the study period, plasma samples were obtained from all blood samples collected from patients at admission in Emergency Department for the study of myocardial enzymes. Plasma samples were obtained (heparin-litio BD Vacutanier®) after centrifugation of blood samples during seven minutes at 3500 revolutions per minute, divided into aliquots of 0.5 ml (ml), stored at −40 °C and saved until their analysis. Only plasma samples of patients included in the study were analyzed. Samples from patients not included in the study were eliminated following the protocol of the biochemical laboratory, at the time the patient was excluded from the study.

HGF was measured in plasma samples by an enzyme-linked immunosorbent assay (Abcam®), at the time of evaluation; the lower limit of detection was 3 pg/ml (10% coefficient of variation).

Copeptin was measured in plasma simples by automated immunofluorescent assay for the quantitative determination (Brahms®); the lower limit of
detection was 0.9 pmol/Liter (pmol/L) (20% coefficient of variation).

High-sensitivity Cardiac Troponin I (hs-cTnI) was measured in plasma samples with ADVIA Centaur XP® Tnl-Ultra® assay (Siemens®), at the moment of evaluation and subsequent measurements at six-hour interval until maximum peak was reached. The minimum measurable concentration using this assay with a <10% coefficient variation is 30 nanogram/Liter (ng/L). The samples for creatine-kinase measurement were collected at evaluation in the Emergency Department and processed in an ADVIA Chemistry 1800 analyser (Siemens®).

**Analysis**

We valued if the measured variables followed a normal distribution by using the Kolmogorov–Smirnov test. Those quantitative variables that follow a normal distribution are expressed as means ± S.D. and compared using the Student’s t test; otherwise, those that do not follow a normal distribution variables are shown as medians and interquartile ranges and compared using the Mann–Whitney test. Qualitative variables are shown as percentages and compared by the chi-square test.

The level of statistical significance was set to a $p \leq 0.05$, using bilateral contrasts, and results were expressed with 95% confidence intervals.

Logistic regression models were built for multivariate analysis to identify factors associated with hospital mortality. Univariate analysis of main variables registered was done. Predictor variables that were statistically significant when evaluated individually against hospital mortality were included in the forward stepwise multiple logistic regression analysis. The results are presented as odds ratio with the appropriate 95% confidence interval.

Statistical analysis was performed using SPSS 15.0 software (SPSS Inc. Chicago Illinois).

**Results**

**Characteristics of study subjects**

A total of 303 patients with suspected acute MI (acute chest pain and high levels of hs-cTnI at hospital arrival) were evaluated, but only 84 were finally diagnosed of acute MI and included in the study. The patients included were mostly male (65.5%) with a median age of 70.3 ± 13.56 years, being the most frequent risk factor for ACS the systemic arterial hypertension (75.0%), followed by smoking (59.5%) and dyslipemia (58.3%) (Table 1).

**Main results**

**Hospital mortality**

Of the 84 patients included in the study, 10 (11.9%) died during hospital admission. The deceased patients were older (84.0 ± 9.0 years versus (vs.) 68.4 ± 13.0 years in survivors, $p = 0.001$), had a higher punctuation on GRACE risk score [20] (151.6 ± 27.4 vs. 114.2 ± 33.4 in survivors, $p = 0.001$) and more frequently had prior kidney disease (5 patients (50.0%) vs. 7 patients (9.5%), $p = 0.001$) (Table 1).

Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.6 pmol/L [52.21–588.5] in non-survivors vs. 24.79 pmol/L [10.90–84.82], $p = 0.001$). However, we found no statistically significant association between plasma levels of HGF and hospital mortality (Table 2).

In the multivariate analyses that we performed, we found that only age and copeptin were associated to hospital mortality (Table 3).

**Mortality at one-year follow-up**

Follow-up at 1 year was possible in all patients included in the study. The global mortality at one-year follow-up was 21.43% (18 of the 84 patients included in the study). As occurs in hospital mortality, deceased patients during 1 year follow-up were older (80.2 ± 10.7 years vs. 67.6 ± 13.1 years in survivors, $p > 0.001$), had a higher punctuation on GRACE score [20] (153.8 ± 28.9 vs.109.6 ± 30.3 in survivors, $p > 0.001$) and more frequently had prior kidney disease (7 patients (38.9%) vs. 5 patients (7.6%), $p = 0.001$). They also had more frequent previous history of heart disease, either coronary artery disease (11 patients (61.1%) vs. 17 patients (25.8%), $p = 0.010$), cardiomyopathy (2 patients (11.1%) vs. 0 patients (0.0%), $p = 0.040$) or valvular heart disease (3 patients (16.7%) vs. 1 patient (1.5%), $p = 0.027$) (Table 1).

As in hospital mortality, we found that plasma levels of copeptin at hospital arrival were higher in those patients who died during the following year (112.28 pmol/L [25.10–418.27] in 1-year follow-up non-survivors vs. 23.82 pmol/L [10.96–77.30], $p = 0.02$). In the case of HGF, we also find no association between HGF plasma levels and 1-year follow-up mortality (Table 2).

**Discussion**

Our study has shown that, in unselected patients with acute MI, higher levels of copeptin at hospital arrival were associated to worse prognosis, as it is associated with higher hospital mortality and higher 1-year follow-up mortality. However, we did not find this association with HGF.

Copeptin have been associated with high mortality in patients with suspected acute coronary syndrome at hospital arrival in many previous studies. Balmelli et al. [22] found that high levels of copeptin measured at hospital arrival were associated with worse prognosis: higher hospital mortality and 1-year mortality, in their prospective
study in patients presenting to the Emergency Department with symptoms suggestive of acute MI of less than 12 h; although, in this study, only 15.9% of patients were finally diagnosed of acute MI, being the other diagnoses unstable angina (14.0%), cardiac but noncoronary cause in 13.0%, noncardiac cause of chest pain in 48.4% and remained of unknown origin in 48.4% of patients included in the study. Maisel et al. [23] also found that high levels of copeptin were a powerful predictor of death at 180 days and hospitalization, in patients who arrived at hospital with chest pain within 6 h of pain onset; however, in this study the proportion of patients with acute MI was only 7.9%. Lattuca et al. [24] measured level of copeptin and cardiac troponin I at the beginning of percutaneous coronary intervention in unselected patients with acute ST-segment elevation myocardial

Table 1 Characteristics of study subjects

| All patients (n = 84) | Hospital mortality | 1 year follow-up |
|----------------------|--------------------|------------------|
|                      | Survivors (n = 74) | Non survivors (n = 10) | p   | Survivors (n = 66) | Non survivors (n = 18) | p   |
| Age, years           | 70.3 ± 13.6        | 68.4 ± 13.0       | 84.0 ± 9.0 | 0.001 | 67.6 ± 13.1       | 80.2 ± 10.7 | <0.001 |
| Sex, male            | 55 (65.5%)         | 51 (68.9%)        | 4 (40.0%) | 0.087 | 46 (69.7%)        | 9 (50.0%)   | 0.119  |
| GRACE risk score     | 118.7 ± 34.8       | 114.2 ± 33.4      | 151.6 ± 27.4 | 0.001 | 109.6 ± 30.3       | 153.8 ± 28.9 | <0.001 |
| STEMI                | 25 (29.8%)         | 22 (29.7%)        | 3 (30.0%) | 1.000 | 20 (30.3%)        | 5 (27.8%)   | 0.835  |

Risk factors for ACS

- Systemic hypertension: 63 (75.0%) vs 53 (71.6%) vs 10 (100.0%) (p = 0.060)
- Diabetes mellitus: 37 (44.0%) vs 33 (44.6%) vs 4 (40.0%) (p = 1.000)
- Dislipemia: 49 (58.3%) vs 44 (59.5%) vs 5 (50.0%) (p = 0.570)
- Known family history of cardiovascular diseases: 2 (2.4%) vs 2 (2.7%) vs 0 (0.0%) (p = 1.000)
- Smoking: 50 (59.5%) vs 45 (60.8%) vs 5 (50.0%) (p = 0.520)
- Previous history of coronary artery disease: 28 (33.3%) vs 24 (32.4%) vs 4 (40.0%) (p = 0.720)

Comorbidity:

- Hyperuricemia: 3 (3.6%) vs 2 (2.7%) vs 1 (10.0%) (p = 0.320)
- Kidney disease: 12 (14.3%) vs 7 (9.5%) vs 5 (50.0%) (p = 0.001)
- Lung disease: 15 (17.9%) vs 13 (17.6%) vs 2 (20.0%) (p = 1.000)
- Hepatic disease: 1 (1.2%) vs 1 (1.4%) vs 0 (0.0%) (p = 1.000)
- Cardiomyopathy: 2 (2.4%) vs 1 (1.4%) vs 1 (10.0%) (p = 0.220)
- Valvular heart: 4 (4.8%) vs 3 (4.1%) vs 1 (10.0%) (p = 0.400)

Table 2 Outcomes

| Hospital mortality | 1-year follow-up mortality |
|--------------------|---------------------------|
| Survivors | Non-survivors | p   | Survivors | Non-survivors | p   |
| Copeptin (pmol/L) | 24.79 (10.90–84.82) | 145.60 (52.21–588.50) | 0.01 | 23.82 (10.96–77.30) | 112.28 (25.10–418.27) | 0.02 |
| HGF (pg/ml)       | 355.24 (175.55–521.76) | 381.05 (189.95–736.65) | 0.73 | 345.53 (183.68–561.15) | 350.00 (175.05–555.08) | 0.68 |
| Hs-cTnl at inclusion (ng/ml) | 0.70 (0.15–4.58) | 2.71 (0.53–22.16) | 0.10 | 0.72 (0.17–4.71) | 2.11 (0.28–9.97) | 0.61 |
| Maximum peak Hs-cTnl (ng/ml) | 11.71 (2.64–35.58) | 9.85 (2.41–50.99) | 0.90 | 13.80 (2.50–38.54) | 5.15 (2.87–20.44) | 0.28 |
| Creatine kinase at inclusion (UI/l) | 141.00 (108.00–429.50) | 176.50 (108.5–259.00) | 0.97 | 154.00 (114.00–443.50) | 159.50 (88.25–255.25) | 0.36 |

The results are shown as number and percentage, except those marked with * that are expressed as median ± SD.

ACS Acute coronary syndrome, STEMI ST-segment elevation myocardial infarction.

The results are shown as median (P25–P75).

HGF hepatocyte growth factor.
in patients who died during hospitalization, during the first 30 days after the myocardial infarction and at 1 year follow-up; performed a multivariate analysis associating one year mortality with the presence cardiogenic shock, increasing age, the presence of higher levels of copeptin (> 128.2 pmol/L) and radial access.

It has been demonstrated that the level of copeptin at admission has a superior prognostic compared to peak of cardiac troponin I. In this way, the ConTrACS study [25] evaluated the prognostic value of copeptin, measured at hospital arrival, in symptomatic patients with increased high sensitivity cardiac troponin T presenting to the Emergency Department. They demonstrated that patients with higher levels of copeptin had higher mortality in the entire cohort. Without differences when they analyzed only the group of patients who were finally diagnoses of acute coronary syndrome (> 128.2 pmol/L) and radial access.

Risk factors for ACS:
- Systemic hypertension
- Diabetes mellitus
- Dislipemia
- Known family history of cardiovascular diseases
- Smoking
- Previous history of coronary artery disease

Comorbidty:
- Hyperuricemia
- Kidney disease
- Lung disease
- Hepatic disease
- Cardiomyopathy
- Valvular heart

Multivariate analysis
- Age
- Copeptin

### Table 3  Factors associated to hospital mortality

|                               | Odds ratio (95% CI) | p value |
|-------------------------------|--------------------|---------|
| **Univariate analysis**       |                    |         |
| Age                           | 1.120 (1.03–1.209) | 0.004   |
| Sex                           | 0.295 (0.08–1.086) | 0.066   |
| HGF                           | 1.000 (0.999–1.001)| 0.713   |
| Troponin at admission         | 1.030 (0.993–1.069)| 0.114   |
| Higher troponin               | 0.999 (0.989–1.010)| 0.917   |
| Copeptin                      | 1.001 (1.001–1.007)| 0.006   |
| TIMI                          | 0.887 (0.571–1.380)| 0.596   |
| GRACE                         | 1.031 (1.009–1.054)| 0.005   |
| GRACE > 140                   | 8.121 (1.980–33.317)| 0.004   |
| STEMI                         | 1.176 (0.287–4.822)| 0.822   |
| **Risk factors for ACS:**    |                    |         |
| Systemic hypertension         | 2.352E (0.000)     | 0.998   |
| Diabetes mellitus             | 0.972 (0.277–1.380)| 0.965   |
| Dislipemia                    | 0.750 (0.213–2.643)| 0.654   |
| Known family history of CVD   | 0.000 (0.00)       | 0.999   |
| Smoking                       | 0.716 (0.203–2.525)| 0.603   |
| Previous history of ACS       | 1.613 (0.456–5.706)| 0.548   |
| **Comorbidty:**               |                    |         |
| Hyperuricemia                 | 6.519 (0.959–44.292)| 0.055   |
| Kidney disease                | 7.933 (1.926–29.937)| 0.004   |
| Lung disease                  | 1.521 (0.366–6.315)| 0.564   |
| Hepatic disease               | 0.000 (0.00)       | 1.000   |
| Cardiomyopathy                | 9.000 (0.522–155.242)| 0.130   |
| Valvular heart                | 2.933 (0.278–30.936)| 0.371   |
| **Multivariate analysis**     |                    |         |
| Age                           | 1.138 (1.033–1.253)| 0.009   |
| Copeptin                      | 1.005 (1.001–1.009)| 0.011   |

ACS Acute coronary syndrome, HGF hepatocyte growth factor

they found that the 30 days follow-up mortality were associated with higher levels of copeptin (4.5% vs 0.4% in patients with normal copeptin values, <0.0001). Zellweger et al. [26] demonstrated that copeptin was strongly and independently associated with death during 720 days follow-up in diabetic patients with acute MI; even in those in which the diagnosis of acute MI was not finally confirmed.

One recent meta-analysis [27] evaluated the prognostic value of copeptin in patients with acute coronary syndrome and concluded that elevated copeptin was associated with higher mortality with a pooled sensitivity of 0.77% (95% CI: 0.59–0.89) and a pooled specificity of 0.60 (95% CI: 0.47–0.71). It included 6 studies, with a variable follow-up period between 30 days and 1 year.

Also, copeptin has been related with the development of post MI complications, as development of left ventricular dysfunction and heart failure after MI, what influences acute MI mortality [8, 9, 28].
In patients with ischemic heart disease, the prognosis value of serum levels of HGF has demonstrated contradictory results. In our study, we did not find an association between HGF levels and worse outcome in patients with acute MI.

Some authors have related high levels of HGF with a better prognosis. So, Yasuda et al. [29] measured HGF levels in 40 patients with acute MI who underwent coronary reperfusion therapy upon admission. They found an enhanced HGF secretion from the infarct region, which correlated inversely with the left ventricular end-diastolic volume index, left ventricular end-diastolic pressure and tau, and positively with left ventricular ejection fraction; so, they concluded that enhanced HGF secretion is associated with attenuation of ventricular remodeling and improvement in cardiac function. Heeschen et al. [30] found that high HGF serum levels in patients with refractory unstable angina were associated with low incidence of death and nonfatal myocardial infarction at six-month follow-up; although in this study, patients with higher HGF levels had more frequently collateral circulation and partial or complete retrograde filling in coronary angiogram study.

On the other hand, some studies show that HGF levels are significantly higher in patients with worse prognosis. Konopka et al. [12] measured levels of HGF as soon as possible after admission to hospital and 24 h afterward, in 104 patients with the first episode of ACS who were eligible for coronary angiography and, eventually, percutaneous coronary intervention. They found that 33 patients (32%) suffered the primary outcome of the study (a composite endpoint of death, MI, exacerbation of angina, heart failure, cardiovascular re-intervention, rehospitalization due to cardiovascular causes and stroke). On them, the concentration of HGF observed was significantly higher than in patients without any complication, classified as the primary outcome during the three-month follow-up. This authors also measured HGF levels in 6 patients with acute MI during the first day of ACS (repeated 10 times during the first day) and once at discharge from hospital; and found a marked increase in HGF levels in the first measurement, that were reduced to almost normal values within 5 h, with a second increase of HGF levels during the first 24 h in those patients who had serious cardiovascular events in the acute stage of MI (cardiac arrest and early re-occlusion of the coronary artery) [31]. Lamblin et al. [14] found that levels of HGF were higher in patients who died or were rehospitalized for heart failure during 1-year follow-up after a first anterior wall Q-wave MI. Susen et al. [18] measured HGF levels at admission in 488 patients with acute MI referred for percutaneous coronary revascularization who were not receiving heparin and found that serum HGF levels were a strong and independent predictor of worse clinical events (a composite of death and non-fatal MI) during a median follow-up period of 14.9 months.

This study had several limitations. First, HGF and copeptin samples were obtained in a variable time since onset of symptoms, hence the rapid changes in serum levels may affect the results. Second, we did not make serial determinations of copeptin nor HGF, to see the evolution and peak maximum. Third, we cannot quantify exactly the clinical benefit associated with an improved risk stratification based on copeptin levels. Fourth, our study is only a descriptive study, not an interventional one, so we cannot evaluate the clinical impact of measurement of HGF and copeptin at hospital arrival.

Future studies are warranted to examine if those patients with high levels of copeptin could possibly benefit from revascularization of all the lesions found in the coronary angiography, prolong admission to the coronary unit or reinforcement of antiplatelet treatment, or even, anticoagulation therapy; closer follow-up or more rigorous control of treatment and risk factors. Fifth, we did not assess the relationship between the treatment received, HGF and copeptin levels and mortality.

We consider that the main strength of our study is that it has allowed us to obtain real world data, since it was carried-out under conditions of daily clinical practice.

Conclusions
In conclusions, in patients with acute MI measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of HGF measurement.

Abbreviations
ACS: Acute coronary syndrome; GRACE: Global Registry of Acute Coronary Events; HGF: Hepatocyte growth factor; hs-cTnI: High-sensitivity Cardiac Troponin I; L: Liter; MI: Myocardial infarction.; ml: Milliliters; ng: Nanogram; pmol: Picomole; TIMI: Thrombolysis in myocardial infarction; vs.: Versus.

Acknowledgements
We wanted to thank all staff and patients of Principe de Asturias University Hospital that have worked or collaborated selflessly in this study.

Author contributions
MCP, IA and RP designed the study. MCP, LM and MT recorded the data of the patients. MCP, LM, IA, MT and RP analyzed and interpreted the data. RP and MCP have drafted the work. All authors read and approved the final manuscript.

Funding
This study did not receive financial or logistical support from any institution outside the Service or the Hospital where the study was carried out.
Availability of data and materials
The datasets generated and/or analyzed during the study are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate
The study was approved by the Institutional Ethics and Clinical Trials Committee of University Hospital Príncipe de Asturias (Alcalá de Henares, Madrid, Spain). Written informed consent was obtained from the patients.

Consent for publication
Not applicable.

Competing interests
Neither, the researchers nor the subjects recruited in this study, received any fees or material incentives for their participation. The authors declare that there is no conflict of interest.

Author details
1. Critical Care Unit, Hospital Universitario Príncipe de Asturias, Carretera Alcalá-Meco SN, 28805 Alcalá de Henares, Madrid, Spain. 2. University of Alcalá, Alcalá de Henares, Madrid, Spain. 3. Department of Biochemistry, Hospital Universitario Príncipe de Asturias, Carretera Alcalá-Meco SN, 28805 Alcalá de Henares, Madrid, Spain. 4. Department of Biochemistry, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo Km 9.100, 28034 Madrid, Spain. 5. Critical Care Unit, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo Km 9.100, 28034 Madrid, Spain.

Received: 17 August 2021   Accepted: 20 April 2022

Published online: 28 April 2022

References
1. Collet JP, Thiele H, Barbato E et al (2020) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistenST-segment elevation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa575
2. Ibañez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 70:1082. https://doi.org/10.1016/j.rec.2017.11.010
3. Schurtz G, Lamblin N, Bauters C et al (2015) Copeptin in acute coronary syndromes and heart failure management: state of the art and future directions. Arch Cardiovasc Dis 108:398–407. https://doi.org/10.1016/j.acvd.2015.04.002
4. Meune C, Zuily S, Wahby K et al (2011) Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: a pilot study. Arch Cardiovasc Dis 104:4–10. https://doi.org/10.1016/j.acvd.2011.10.002
5. Lippi G, Plebani M, Di Somma S et al (2012) Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clin Chem Lab Med 50:245–253. https://doi.org/10.1515/cclm-2011-0845
6. Raskoalova T, Twenboldt R, Collinson PO et al (2014) Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 3:18–27. https://doi.org/10.11177/2048872613510415
7. O’Malley RG, Bonaca MP, Scirica BM et al (2014) Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol 63:1644–1653. https://doi.org/10.1016/j.jacc.2013.12.034
8. Khan SQ, Dhillon OS, O’Brien RJ et al (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103–2110. https://doi.org/10.1161/CIRCULATIONAHA.106.685503
9. Kelly D, Squire IB, Khan SQ et al (2008) C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 14:739–745. https://doi.org/10.1016/j.cardfail.2008.07.231
10. Voors AA, von Haeling S, Anker SD et al (2009) C-terminal provasopres‑ sin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30:1187–1194. https://doi.org/10.1093/eurheartj/ehp098
11. Nakamura T, Mizuno S (2010) The discovery of copeptin and its potential for diagnosis of acute coronary syndromes in patients without persistent ST-segment elevation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehp098
12. Konopka A, Janas J, Piotrowski W et al (2010) Hepatocyte growth factor–a new marker for prognosis in acute coronary syndrome. Growth Factors 28:75–81. https://doi.org/10.3109/08977190903403984
13. Jimenez-Navarro MF, Gonzalez FJ, Caballero-Borrego J et al (2011) Coronary disease extension determines mobilization of endothelial progenitor cells and cytokines after a first myocardial infarction with ST elevation. Rev Esp Cardiol 64:1123–1129. https://doi.org/10.1016/j.recesp.2011.07.003
14. Lamblin N, Bauters A, Fertin M et al (2011) Circulating levels of hepatocyte growth factor and left ventricular remodelling after acute myocardial infarction from the REVE‑2 study. Eur J Heart Fail 13:1314–1322. https://doi.org/10.1002/ejhf.hfi.157
15. Nishimura M, Ushiyama M, Nanbu A et al (1997) Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens 15:1113–1114
16. Yoshitomi Y, Kojima S, Unemoto T et al (1999) Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Endocri‑ nol Metab 84:2425–2428. https://doi.org/10.1210/esc.84.7.5826
17. Decker PA, Larson NB, Bell EJ et al (2019) Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: the Multi‑Ethnic Study of Atherosclerosis (MESA). Am Heart J 213:30–34. https://doi.org/10.1016/j.ahj.2019.03.018
18. Susen S, Sautiere K, Mouquet F et al (2005) Serum hepatocyte growth factor levels predict long‑term clinical outcome after percutaneous coronary revascularization. Eur Heart J 26:2387–2395. https://doi.org/10.1093/eurheartj/ehi436
19. Thygensen K, Alpert JS, Jaffe AS et al (2018) Fourth Universal Definition of Myocardial Infarction. Circulation 138:e618–e651. https://doi.org/10.1161/CIR.0000000000000617
20. Antman EM, Cohen M, Bernink PJ et al (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prog nostication and therapeutic decision making. JAMA 284:855–862
21. Balmelli C, Meune C, Twenboldt R et al (2013) Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. Am Heart J 166:30–37. https://doi.org/10.1016/j.ahj.2013.03.014
22. Masel A, Mueller C, Neath SK et al (2013) Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early Detection Of Patients with acute myocardial Infarction). J Am Coll Cardiol 62:150–160. https://doi.org/10.1016/j.jacc.2013.04.011
23. Lattuca B, Sy V, Nguyen LS et al (2019) Copeptin as a prognostic bio‑ marker in acute myocardial infarction. Int J Cardiol 274:337–341. https://doi.org/10.1016/j.ijcard.2018.09.022
24. Waldspurger H, Biener M, Stoyanov KM et al (2020) Prognostic value of elevated copeptin and high‑sensitivity cardiac troponin t in patients with and without acute coronary syndrome: the ConTrACS Study. J Clin Med. https://doi.org/10.3390/jcm9113627
25. Zellweger C, Wild T, Twenboldt R et al (2015) Use of copeptin and high‑sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction. Int J Cardiol 190:190–197. https://doi.org/10.1016/j.ijcard.2015.04.134
27. Lu J, Wang S, He G et al (2020) Prognostic value of copeptin in patients with acute coronary syndrome: a systematic review and meta-analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0238288
28. Xu L, Liu X, Wu S et al (2018) The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction: a cross-sectional study. Medicine (Baltimore) 97:e12610. https://doi.org/10.1097/MD.00000000000012610
29. Yasuda S, Goto Y, Baba T et al (2000) Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 36:115–121. https://doi.org/10.1016/s0735-1097(00)00675-6
30. Heeschen C, Dimmeler S, Hamm CW et al (2003) Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107:524–530
31. Konopka A, Janas J, Stepinska J (2012) Hepatocyte growth factor concentration during the first day of acute coronary syndrome. Arch Med Sci 8:389–391. https://doi.org/10.5114/aoms.2012.28571

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.